title: Epigenetic modification boosts ovarian cancer vaccination.
authors.forename: Ramla
authors.initials: R
authors.lastname: Benmaamar
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D003131:Combined Modality Therapy; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000187:drug effects*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008565:Membrane Proteins / Q000276:immunology / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine